Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 3:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 2,123 matching trials from the live ClinicalTrials.gov search.
Conditions
Solid Malignancies
Interventions
Gimatecan® (ST-1481)
Drug
Lead sponsor
Sigma-Tau Research, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
3
States / cities
Boston, Massachusetts • Providence, Rhode Island
Conditions
Metastatic or Incurable Non-small Cell Lung Cancer, Relapsed, Refractory Melanoma
Interventions
omaveloxolone
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
recombinant interferon alfa, recombinant interleukin-12
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
13 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Cervical Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer, Malignant Mesothelioma, Ovarian Cancer, Pancreatic Cancer, Primary Peritoneal Cavity Cancer
Interventions
SS1(dsFv)-PE38 immunotoxin
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
2
States / cities
Bethesda, Maryland • Winston-Salem, North Carolina
Conditions
Advanced Solid Tumors
Interventions
BPT567
Drug
Lead sponsor
Bright Peak Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
7
States / cities
Scottsdale, Arizona • Grand Rapids, Michigan • Hackensack, New Jersey + 4 more
Conditions
Advanced or Metastatic Solid Tumors
Interventions
TAS0612
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Nashville, Tennessee • Houston, Texas
Conditions
Non-small Cell Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Other Metastatic Solid Tumors
Interventions
JAB-3068
Drug
Lead sponsor
Jacobio Pharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
4
States / cities
Denver, Colorado • Sarasota, Florida • Nashville, Tennessee + 1 more
Conditions
Cancers
Interventions
NM6603
Drug
Lead sponsor
NucMito Pharmaceuticals Co. Ltd.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Detroit, Michigan • Cleveland, Ohio • Nashville, Tennessee + 1 more
Conditions
Solid Tumor, Adult, Metastasis
Interventions
Palliative and Survivorship Care Model
Behavioral
Lead sponsor
Good Samaritan Hospital Medical Center, New York
Other
Eligibility
21 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
West Islip, New York
Conditions
Neoplasms, Lymphoma
Interventions
IPdR
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 110 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Cancer
Interventions
capecitabine, irinotecan hydrochloride
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Solid Tumor
Interventions
AT-1965 Liposome Injection
Drug
Lead sponsor
Alyssum Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
9
States / cities
Scottsdale, Arizona • Bakersfield, California • El Segundo, California + 5 more
Conditions
Malignant Solid Tumor
Interventions
Ramucirumab, Docetaxel
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
6
States / cities
Ann Arbor, Michigan • Detroit, Michigan • New Brunswick, New Jersey + 3 more
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor, Solid Tumor
Interventions
BGB-A3055, Tislelizumab, Chemotherapy
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
Orlando, Florida • Iowa City, Iowa • Hackensack, New Jersey + 3 more
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
epirubicin hydrochloride, irinotecan hydrochloride
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Neoplasms
Interventions
BAY79-4620
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Nashville, Tennessee • San Antonio, Texas
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
gemcitabine hydrochloride, paricalcitol
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Endometrial Cancer, Endometrial Cancer Recurrent, Lung Cancer Recurrent, Lung Cancer, Non-small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma
Interventions
RGX-104, Ipilimumab, Docetaxel, Pembrolizumab, Carboplatin, Pemetrexed
Drug
Lead sponsor
Inspirna, Inc.
Industry
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
21
States / cities
Tucson, Arizona • Los Angeles, California • Aurora, Colorado + 16 more
Conditions
Locally Advanced Solid Tumours, Metastatic Solid Tumours, Ovarian Cancer
Interventions
AZD1775
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Scottsdale, Arizona • Denver, Colorado • Nashville, Tennessee
Conditions
Solid Tumor, Lymphoma
Interventions
DZ-002
Drug
Lead sponsor
Da Zen Theranostics Inc
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Metastatic Solid Tumor, Lymphoma, Myeloproliferative Neoplasms (MPN)
Interventions
PU-H71
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
1
States / cities
New York, New York
Conditions
Solid Tumors, KRAS Mutation; SOS1
Interventions
BI 1701963, Trametinib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
4
States / cities
Boston, Massachusetts • Charlotte, North Carolina • Nashville, Tennessee + 1 more
Active, not recruiting Phase 2 Interventional Results available

Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer

NCT01949662
Conditions
Advanced Cancers
Interventions
Lorazepam, Placebo, Haloperidol decanoate, Questionnaires
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
Houston, Texas
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
1-methyl-d-tryptophan, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Tampa, Florida • Richmond, Virginia